{"success":true,"data":{"pressRelease":{"id":"154520","rtpr_id":"nBwDYR1Na-20260928","ticker":"DFTX","exchange":"NASDAQ","all_tickers":["DFTX"],"title":"Definium Therapeutics Announces New Employee Inducement Grants","author":"Business Wire","published_at":"2026-09-28T20:01:00.072Z","article_body":"Definium Therapeutics Announces New Employee Inducement Grants\n\nDefinium Therapeutics, Inc. (“Definium” or the “Company”), a\nlate-stage clinical biopharmaceutical company developing a new generation of\ntherapeutics intended to address underlying causes of psychiatric and\nneurological disorders, today announced the issuance of inducement grants to\nfifteen newly hired non-executive employees consisting of options to purchase\nan aggregate of 334,810 common shares of the Company (the \"Options\") with\neffective grant dates of September 28, 2026. The Options have an exercise\nprice equal to the closing price of Definium’s common shares on the date of\nthe grants, and will vest over a four-year period with 25% vesting on the\nfirst anniversary of the date of the grant and the remaining 75% vesting in\nsubstantially equal monthly increments over the three-year period thereafter,\nsubject to each employee’s continued employment.\n\nThe Options were granted as a material inducement to each employee’s\nemployment and were approved by Definium's Compensation Committee on September\n27, 2026, in accordance with Rule 5635(c)(4) of The NASDAQ Stock Market LLC.\nThe Options were granted pursuant to Definium’s 2026 Inducement Plan.\n\nAbout Definium Therapeutics\n\nThe mission of Definium Therapeutics is to forge a new era of psychiatry by\napplying scientific rigor to psychedelics, with the goal of developing\naccessible treatments that unlock healing at scale. Guided by a recognition\nthat patients deserve more than better, Definium is relentlessly advancing a\nnew generation of therapeutics intended to address underlying causes of\npsychiatric and neurological disorders. By turning evidence into impact,\nDefinium aims to change the trajectory of today’s mental health care crisis\nand enable a healthier future. Headquartered in New York, Definium\nTherapeutics trades on Nasdaq under the symbol DFTX.\n\nFor more information, visit https://definiumtx.com/\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fdefiniumtx.com%2F&esheet=54612216&newsitemid=20260928755596&lan=en-US&anchor=https%3A%2F%2Fdefiniumtx.com%2F&index=1&md5=e06db048d8ff5ae93459f5667e46d4ad)\nand follow Definium Therapeutics on Instagram\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.instagram.com%2Fdefiniumtherapeutics%2F&esheet=54612216&newsitemid=20260928755596&lan=en-US&anchor=Instagram&index=2&md5=6dcc50c9a14b2db877227195f25e2373)\n, LinkedIn\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fdefiniumtherapeutics&esheet=54612216&newsitemid=20260928755596&lan=en-US&anchor=LinkedIn&index=3&md5=6eeb2bf494207698554ced6b37aaf135)\nand X\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fx.com%2Fdefiniumtx&esheet=54612216&newsitemid=20260928755596&lan=en-US&anchor=X&index=4&md5=3a7c5ed277a547515454591047624326)\n.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260928755596/en/\n(https://www.businesswire.com/news/home/20260928755596/en/)\n\nInvestors: \n\nGitanjali Jain\n\nVP, Head of Investor Relations\n\nir@definiumtx.com (mailto:ir@definiumtx.com)\n\nMedia: \n\nmedia@definiumtx.com (mailto:media@definiumtx.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBwDYR1Na-20260928","title":"Definium Therapeutics Announces New Employee Inducement Grants","author":"Business Wire","ticker":"DFTX","created":"2026-09-28T20:01:00.072Z","tickers":["DFTX"],"exchange":"NASDAQ","article_body":"Definium Therapeutics Announces New Employee Inducement Grants\n\nDefinium Therapeutics, Inc. (“Definium” or the “Company”), a\nlate-stage clinical biopharmaceutical company developing a new generation of\ntherapeutics intended to address underlying causes of psychiatric and\nneurological disorders, today announced the issuance of inducement grants to\nfifteen newly hired non-executive employees consisting of options to purchase\nan aggregate of 334,810 common shares of the Company (the \"Options\") with\neffective grant dates of September 28, 2026. The Options have an exercise\nprice equal to the closing price of Definium’s common shares on the date of\nthe grants, and will vest over a four-year period with 25% vesting on the\nfirst anniversary of the date of the grant and the remaining 75% vesting in\nsubstantially equal monthly increments over the three-year period thereafter,\nsubject to each employee’s continued employment.\n\nThe Options were granted as a material inducement to each employee’s\nemployment and were approved by Definium's Compensation Committee on September\n27, 2026, in accordance with Rule 5635(c)(4) of The NASDAQ Stock Market LLC.\nThe Options were granted pursuant to Definium’s 2026 Inducement Plan.\n\nAbout Definium Therapeutics\n\nThe mission of Definium Therapeutics is to forge a new era of psychiatry by\napplying scientific rigor to psychedelics, with the goal of developing\naccessible treatments that unlock healing at scale. Guided by a recognition\nthat patients deserve more than better, Definium is relentlessly advancing a\nnew generation of therapeutics intended to address underlying causes of\npsychiatric and neurological disorders. By turning evidence into impact,\nDefinium aims to change the trajectory of today’s mental health care crisis\nand enable a healthier future. Headquartered in New York, Definium\nTherapeutics trades on Nasdaq under the symbol DFTX.\n\nFor more information, visit https://definiumtx.com/\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fdefiniumtx.com%2F&esheet=54612216&newsitemid=20260928755596&lan=en-US&anchor=https%3A%2F%2Fdefiniumtx.com%2F&index=1&md5=e06db048d8ff5ae93459f5667e46d4ad)\nand follow Definium Therapeutics on Instagram\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.instagram.com%2Fdefiniumtherapeutics%2F&esheet=54612216&newsitemid=20260928755596&lan=en-US&anchor=Instagram&index=2&md5=6dcc50c9a14b2db877227195f25e2373)\n, LinkedIn\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fdefiniumtherapeutics&esheet=54612216&newsitemid=20260928755596&lan=en-US&anchor=LinkedIn&index=3&md5=6eeb2bf494207698554ced6b37aaf135)\nand X\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fx.com%2Fdefiniumtx&esheet=54612216&newsitemid=20260928755596&lan=en-US&anchor=X&index=4&md5=3a7c5ed277a547515454591047624326)\n.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260928755596/en/\n(https://www.businesswire.com/news/home/20260928755596/en/)\n\nInvestors: \n\nGitanjali Jain\n\nVP, Head of Investor Relations\n\nir@definiumtx.com (mailto:ir@definiumtx.com)\n\nMedia: \n\nmedia@definiumtx.com (mailto:media@definiumtx.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-09-28T20:01:00.147831607Z","server_sent_at_ms":1790625660147},"received_at":"2026-09-28T20:01:00.245Z","source_url":"https://www.businesswire.com/news/home/20260928755596/en/"},"analysis":{"id":"143282","press_release_id":"154520","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Definium Therapeutics granted inducement options to purchase an aggregate of 334,810 common shares to fifteen newly hired non-executive employees.\n\nThe grants carry an exercise price equal to the closing price on the September 28, 2026 grant date and vest over four years, with 25% at the first anniversary.\n\nThe awards were made under the company's 2026 Inducement Plan in accordance with NASDAQ Rule 5635(c)(4) and require no shareholder approval; the disclosure is routine boilerplate with no earnings or strategic implications.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine inducement grant disclosure -- suppress from alerts."},"keyFigures":{"customDimensions":{"vesting":"4-year vest; 25% at first anniversary, remainder monthly over 3 years","new_employees":15,"options_granted":334810}},"namedEntities":{"people":[{"name":"Gitanjali Jain","role":"VP, Head of Investor Relations"}],"products":[],"companies":[{"name":"Definium Therapeutics, Inc.","ticker":"DFTX","relationship":"filer"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine NASDAQ Rule 5635(c)(4) employee inducement grants to 15 new non-executive hires; no executive compensation, no financial impact, boilerplate disclosure."},"tickerRelevance":{"others":[],"primary":"DFTX"},"globalImportance":5,"audienceRelevance":5,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap-clinical-stage","eventGravity":"boilerplate-inducement-grants","issuerAuthored":true}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Definium Therapeutics granted inducement options to purchase an aggregate of 334,810 common shares to fifteen newly hired non-executive employees.\n\nThe grants carry an exercise price equal to the closing price on the September 28, 2026 grant date and vest over four years, with 25% at the first anniversary.\n\nThe awards were made under the company's 2026 Inducement Plan in accordance with NASDAQ Rule 5635(c)(4) and require no shareholder approval; the disclosure is routine boilerplate with no earnings or strategic implications.","key_figures":{"customDimensions":{"vesting":"4-year vest; 25% at first anniversary, remainder monthly over 3 years","new_employees":15,"options_granted":334810}},"named_entities":{"people":[{"name":"Gitanjali Jain","role":"VP, Head of Investor Relations"}],"products":[],"companies":[{"name":"Definium Therapeutics, Inc.","ticker":"DFTX","relationship":"filer"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-28T20:01:04.309Z","global_importance":5,"audience_relevance":5,"importance_components":{"tickerTier":"small-cap-clinical-stage","eventGravity":"boilerplate-inducement-grants","issuerAuthored":true}},"durationMs":4028,"modelName":"glm-5.3-flashx"}}